Santé covers FDA Fast Track designation for KST-6051 by Kestrel
Kestrel receives designation for its pan-KRAS inhibitor targeting mutant tumors, enabling expedited review and closer FDA communication.
See the latest news and media coverage for Santé. We track all announcements, press releases, and industry mentions in real time, all in one place.
Healthcare and technology investment firm
sante.comLast updated
In short: Santé raised a record $330M Fund V and advanced portfolio companies across financing rounds, clinical milestones, and regulatory designations.
Kestrel receives designation for its pan-KRAS inhibitor targeting mutant tumors, enabling expedited review and closer FDA communication.
Funding supports clinical studies for CNRT therapy targeting chronic moderate-to-severe traumatic brain injury patients.
The new platform unites predictive, real-time and retrospective AI to improve procedural efficiency and safety.
350 patients enrolled across US and Australia, advancing FDA approval for type 2 diabetes treatment.
Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target the mechanism that makes these...
Celltrion (KRX: 068270) announced today the launch in Europe of the 300 mg dosage of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria...
Traders are rapidly marking up prices for Santé Cie SAS’s loan after the home healthcare provider sa...
Venture capital firm Santé Ventures announced the close of its largest fund to date, raising $330 million in committed capital, exceeding its $300 million target...
Track Santé and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Santé and other trending companies.